임상 레이더 AI | ||
|---|---|---|
임상시험 NCT02650401 (STARTRK-NG)은(는) 고형 종양들, 중추신경계 종양에 대해 진행중, 모집종료 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기
로슈Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) 1상, 2상 69 용량 증량 소아 청소년 오픈 라벨
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT02650401 (STARTRK-NG)은(는) 치료을(를) 알아보기 위한 연구입니다. 이 연구는 고형 종양들, 중추신경계 종양에 대해 진행되며, 1상 2상 중재연구으로 현재 상태는 진행중, 모집종료입니다. 연구는 2016년 5월 3일에 시작되어 69명의 참여자를 모집하고 있습니다. 로슈이(가) 진행하며, 2026년 6월 30일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 25일에 갱신되었습니다.
간단한 개요
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
공식 제목
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
질환명
고형 종양들중추신경계 종양출판물
이 임상시험에 대해 발표된 과학 논문 및 연구 자료.기타 연구 식별자
- STARTRK-NG
- RXDX-101-03
- CO40778 (기타 식별자) (Hoffmann-La Roche)
- 2023-505088-35-00 (EU 시험 (CTIS) 번호)
NCT 번호
실제 연구 시작일
2016-05-03
최신 업데이트 게시
2026-03-25
예상 연구 완료일
2026-06-30
계획된 등록 인원
69
연구종류
중재연구
단계/상
1상
2상
2상
상태
진행중, 모집종료
키워드
TRK
Tyrosine kinase
NTRK
NTRK1
NTRK2
NTRK3
ROS1
ALK
Pediatric
Relapsed
Refractory
Solid Tumor
Metastatic Cancer
Gene rearrangement
Neuroblastoma
Infantile fibrosarcoma
Secretory breast cancer
Congenital mesoblastic nephroma
Pontine glioma
Brain tumors
CNS tumors
Sarcoma
Ewing sarcoma
Glial tumors
Salivary Gland Cancer (MASC)
Papillary thyroid cancer
Medulloblastoma
Wilms tumor (anaplastic)
Tyrosine kinase
NTRK
NTRK1
NTRK2
NTRK3
ROS1
ALK
Pediatric
Relapsed
Refractory
Solid Tumor
Metastatic Cancer
Gene rearrangement
Neuroblastoma
Infantile fibrosarcoma
Secretory breast cancer
Congenital mesoblastic nephroma
Pontine glioma
Brain tumors
CNS tumors
Sarcoma
Ewing sarcoma
Glial tumors
Salivary Gland Cancer (MASC)
Papillary thyroid cancer
Medulloblastoma
Wilms tumor (anaplastic)
주요 목적
치료
설계 할당
비랜덤화 배정
중재 모델
단일군설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
활성 대조군Extracranial solid tumors harboring NTRK1/2/3, Arm closed for further enrollment
ROS1, ALK non-gene fusion molecular alterations
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
활성 대조군CNS tumors harboring- NTRK1/2/3, ROS1, ALK Arm closed for further enrollment
molecular alterations, including gene fusions
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
활성 대조군Neuroblastoma Arm closed for further enrollment
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
활성 대조군Non-neuroblastoma, extracranial solid tumors Arm closed for further enrollment
harboring - NTRK1/2/3, ROS1, ALK gene fusions
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
활성 대조군Any participant unable to swallow capsules Arm closed for further enrollment
Any participant who otherwise meet all other eligibility criteria
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
활성 대조군Expansion: CNS tumors harboring NTRK1/2/3, ROS1 gene fusions
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
활성 대조군Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1 NTRK 1,2,3 and ROS1 fusions
Oral entrectinib (RXDX-101) | Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Maximum Tolerated Dose (MTD) | Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) | Approximately 6 months |
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules | Assessed by NCI CTCAE v4.03 | Approximately 6 months |
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules | Assessed by NCI CTCAE v4.03 | Approximately 6 months |
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube) | Assessed by NCI CTCAE v4.03 | Approximately 6 months |
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules | Assessed by NCI CTCAE v4.03 | Approximately 6 months |
Cohort B: Objective Response Rate (ORR) | Assessed by RANO per the BICR | Approximately 6 months |
Cohort D: ORR | Assessed by RECIST v1.1 per the BICR | Approximately 6 months |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03 | AE, ECG and Labs assessed by NCI CTCAE v4.03 | Approximately 24 months |
Maximum observed plasma drug concentration (Cmax) using F1 Formulation | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Maximum observed plasma drug concentration (Cmax) using minitablets/F15 | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Time to Cmax, by inspection (Tmax) using F1 Formulation | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Time to Cmax, by inspection (Tmax) using minitablets/F15 | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
AUC at steady state (AUCss) using F1 Formulation | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
AUC at steady state (AUCss) using F06 Formulation given intact | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
AUC at steady state (AUCss) using minitablets/F15 | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Terminal half life (t½) using F1 Formulation | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Terminal half life (t½) using F06 Formulation given intact | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Terminal half life (t½) using F06 Formulation administered via feeding tube | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Terminal half life (t½) using minitablets/F15 | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Area under the drug concentration by time curve (AUC) using F1 Formulation | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Area under the drug concentration by time curve (AUC) using minitablets/F15 | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter | Approximately 24 months |
Cohort A, D, or E: Clinical Benefit Rate (CBR) | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Cohort B or E: CBR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Cohort C: CBR | Assessed by the Curie scale per the BICR and investigator | Approximately 6 months |
Cohort A, D, or E: Progression-free Survival (PFS) | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Cohort B or E: PFS | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Cohort C: PFS | Assessed by the Curie scale per the BICR and investigator | Approximately 6 months |
Cohort A, D, or E: Overall Survival (OS) | Assessed by RECIST v1.1 | Approximately 6 months |
Cohort B or E: OS | Assessed by RANO | Approximately 6 months |
Cohort A, D, or E: ORR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Cohort B or E: ORR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Cohort C: ORR | Assessed by the Curie scale per the BICR and investigator | Approximately 6 months |
Cohort A, D, or E: Time to response (TTR) | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Cohort B or E: TTR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Cohort C: TTR | Assessed by the Curie scale per the BICR and investigator | Approximately 6 months |
Cohort A, D, or E: Duration of Response (DOR) | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Cohort B or E: DOR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Cohort C: DOR | Assessed by the Curie scale per the BICR and investigator | Approximately 6 months |
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR | Assessed by RANO per the investigator | Approximately 6 months |
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR | Assessed by RECIST v1.1 per the investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR | Assessed by RECIST v1.1 per the BICR and investigator | Approximately 6 months |
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR | Assessed by RANO per the BICR and investigator | Approximately 6 months |
참여 도우미
적격성 기준
연령대
어린이, 성인
최소 연령
0 Years
참여 가능한 성별
전체
Disease status:
Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
Tumor type:
Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
Archival tumor tissue from diagnosis or, preferably, at relapse
Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
Adequate organ and neurologic function
Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug
- Receiving other experimental therapy
- Known congenital long QT syndrome
- History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
- Known active infections
- Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
- Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
- Prior treatment with approved or investigational TRK or ROS1 inhibitors
- Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
- Patients with NB with bone marrow space-only disease
- Incomplete recovery from acute effects of any surgery prior to treatment.
- Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
- Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
로슈연락처 정보가 없습니다.
26 9개국에 임상시험 장소
California
University of California San Diego, La Jolla, California, 92093-0706, United States
UCSF Benioff Children's Hospital, San Francisco, California, 94158, United States
Colorado
Children's Hospital Colorado, Aurora, Colorado, 80045, United States
Georgia
Egleston Children's Hospital at Emory University Atlanta, Atlanta, Georgia, 30322, United States
Illinois
University of Chicago, Chicago, Illinois, 60637, United States
Maryland
Johns Hopkins University, Baltimore, Maryland, 21205, United States
Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States
Missouri
Washington University,St. Louis Children's Hospital, St Louis, Missouri, 63110, United States
New York
Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States
Ohio
Nationwide Children's Hospital, Columbus, Ohio, 43205, United States
Oregon
Oregon Health & Science Uni, Portland, Oregon, 97239, United States
Pennsylvania
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States
Tennessee
St. Jude Children'S Research Hospital, Memphis, Tennessee, 38105, United States
Texas
Texas Children's Cancer and Hematology Center, Houston, Texas, 77030, United States
Utah
Primary Children's Hospital, Salt Lake City, Utah, 84113, United States
Ontario
The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada
Shanghai Municipality
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, 200082, China
Beijing Children's Hospital, Capital Medical University, Beijing, China
Centre Leon Berard, Lyon, 69373, France
Hôpital de la Timone, Oncologie Pédiatrique, Marseille, 13385, France
Baden-Wurttemberg
Universitaetsklinikum Heidelberg, Heidelberg, Baden-Wurttemberg, 69120, Germany
Hong Kong Children's Hospital, Hong Kong, 00000, Hong Kong
Lombardy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardy, 20133, Italy
Hospital Infantil Universitario Nino Jesus, Madrid, 28009, Spain
Royal Marsden Hospital (Sutton), London, SW3 6JJ, United Kingdom
Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom